Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Biomarker Insights is Scopus-indexed (Q2, CiteScore 4.9), WoS ESCI, DOAJ. Published by SAGE Publications Ltd.
Checked against the index lists dated .
ISSN 1177-2719Verify ISSN ↗
Publisher: SAGE Publications Ltd
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Biochemistry (medical) | 29 / 78 | 63rd | Q2 |
| Pharmacology | 150 / 328 | 54th | Q2 |
| Molecular Medicine | 106 / 179 | 41st | Q3 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2008–present, best quartile Q2, CiteScore 4.9.
Biomarker Insights is Q2 in Biochemistry (medical) (rank 29 of 78), Q2 in Pharmacology (rank 150 of 328) and Q3 in Molecular Medicine (rank 106 of 179), by CiteScore 2025.
Biomarker Insights is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 4.9, which places it in quartile Q2 at the 63rd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.728, quartile Q2, with an H-index of 45.
The publisher lists an article processing charge of about US$2,650 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Biomarker Insights is published by SAGE Publications Ltd. Its ISSN is 1177-2719.
Yes — indexed in the Emerging Sources Citation Index.
Yes — it is an open-access journal, listed in DOAJ.
Biomarker Insights has an h-index of 52 and a 2-year mean of 2.3 citations per paper (OpenAlex). Its Scopus CiteScore is 4.9, quartile Q2. On 2-year citations it ranks #25 of 77 Scopus journals in Biochemistry (medical).
Biomarker Insights published 27 papers in 2025; its busiest recent year was 2022 with 32. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2022–2026), authors are most often from United States (16%), China (10.6%) and Italy (6.8%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.